NEW YORK (GenomeWeb News) – Quest Diagnostics this week said that it completed its acquisition of full-service commercial laboratory firm Solstas Lab Partners Group and its subsidiaries for $570 million. In connection with the deal, Quest raised its guidance for full-year 2014. Revenues are now expected to grow between 2 percent and 4 percent, compared to full-year 2013. It previously said 2014 revenue was anticipated to be flat to down 2 percent year over year, excluding the Solstas purchase.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.